FOLFOX4方案治疗晚期大肠癌的临床观察

Clinical study of FOLFOX4 regimen in treatment of advanced colorectal cancer

为了探讨FOLFOX4方案治疗晚期大肠癌的疗效和安全性,对37例初治或复治的晚期大肠癌患者,予FOL-FOX4方案化疗.全组37例均可评价疗效,初治组部分缓解(PR)7例,稳定(SD)13例,进展(PD)1例,客观有效率为33.3%,中位疾病进展时间8个月,中位生存期14个月;复治组PR 3例,SD11例,PD 2例,客观有效率为18.8%,中位疾病进展时间4个月,中位生存期7个月.毒副反应主要为中性粒细胞减少、消化道反应和神经毒性,均以Ⅰ～Ⅱ度为主,可耐受.初步临床观察结果表明,FOLFOX4方案治疗晚期大肠癌疗效肯定,安全性好,值得积极推广.

The objective of this study was to evaluate the efficiency and toxicity of FOLFOX4 regimen in the treatment of advanced colorectal cancer. Thirty-seven patients with advanced colorectal cancer who had not been treated by chemotherapy or had been untreated were enrolled. The cycles were repeated every 14 days. All patients received two or more cycles. Results all 37 patients were evaluated for efficiency and toxicity. In the untreatment patients, the response rate was 33.3%, including 7 partial response （PR）, 13 stable disease （SD） and 1 progress disease （PD）; the median time to tumor progression was 8 months, and the median overall survival was 14 months. In the treatment patients, the response rate was 18.8%, including 3 PR, 11 SD and 2 PD; the median time to tumor progression was 4 months, and the median overall survival was 7 months. The major toxicities were neutropenia, gastrointestinal toxicity and neurotoxicity, and most of which were Ⅰ - Ⅱgrade. FOLFOX4 regimen is effective and well tolerated for patients with advanced colorectal cancer.